These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 7692137

  • 1. Tenascin staining positivity and the survival of patients with invasive breast carcinoma.
    Shoji T, Kamiya T, Tsubura A, Hamada Y, Hatano T, Hioki K, Morii S.
    J Surg Res; 1993 Sep; 55(3):295-7. PubMed ID: 7692137
    [Abstract] [Full Text] [Related]

  • 2. [Relationship of an extracellular matrix protein, tenascin and breast diseases].
    Ishihara A, Yatani R, Sakakura T.
    Rinsho Byori; 1993 Oct; 41(10):1099-107. PubMed ID: 7504753
    [Abstract] [Full Text] [Related]

  • 3. Simultaneous immunohistochemical and biochemical hormone receptor assessment in breast cancer provides complementary prognostic information.
    Biesterfeld S, Schröder W, Steinhagen G, Koch R, Veuskens U, Schmitz FJ, Handt S, Böcking A.
    Anticancer Res; 1997 Oct; 17(6D):4723-9. PubMed ID: 9494596
    [Abstract] [Full Text] [Related]

  • 4. Reduced tenascin expression in colonic carcinoma with lymphogenous metastasis.
    Sugawara I, Hirakoshi J, Masunaga A, Itoyama S, Sakakura T.
    Invasion Metastasis; 1991 Oct; 11(6):325-31. PubMed ID: 1726610
    [Abstract] [Full Text] [Related]

  • 5. CD44 expression is associated with increased survival in node-negative invasive breast carcinoma.
    Diaz LK, Zhou X, Wright ET, Cristofanilli M, Smith T, Yang Y, Sneige N, Sahin A, Gilcrease MZ.
    Clin Cancer Res; 2005 May 01; 11(9):3309-14. PubMed ID: 15867228
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Triple-negative breast cancer types exhibit a distinct poor clinical characteristic in lymph node-negative Chinese patients.
    Liu ZB, Liu GY, Yang WT, Di GH, Lu JS, Shen KW, Shen ZZ, Shao ZM, Wu J.
    Oncol Rep; 2008 Oct 01; 20(4):987-94. PubMed ID: 18813844
    [Abstract] [Full Text] [Related]

  • 10. Immunohistochemical studies on tenascin in human yellow ligament.
    Fujii Y, Yoshida H, Sakou T.
    In Vivo; 1993 Oct 01; 7(2):143-6. PubMed ID: 7689866
    [Abstract] [Full Text] [Related]

  • 11. [Detection of tenascin in stomach cancer. An immunohistochemical study].
    Broll R, Kayser K, Vollmer G, Plagemann M, Bruch HP.
    Zentralbl Pathol; 1994 Jul 01; 140(2):123-8. PubMed ID: 7524650
    [Abstract] [Full Text] [Related]

  • 12. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival.
    Cheang MC, Treaba DO, Speers CH, Olivotto IA, Bajdik CD, Chia SK, Goldstein LC, Gelmon KA, Huntsman D, Gilks CB, Nielsen TO, Gown AM.
    J Clin Oncol; 2006 Dec 20; 24(36):5637-44. PubMed ID: 17116944
    [Abstract] [Full Text] [Related]

  • 13. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
    Middleton LP, Amin M, Gwyn K, Theriault R, Sahin A.
    Cancer; 2003 Sep 01; 98(5):1055-60. PubMed ID: 12942575
    [Abstract] [Full Text] [Related]

  • 14. Negative margin status improves local control in conservatively managed breast cancer patients.
    Obedian E, Haffty BG.
    Cancer J Sci Am; 2000 Sep 01; 6(1):28-33. PubMed ID: 10696736
    [Abstract] [Full Text] [Related]

  • 15. [The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].
    Voogd AC, Crommelin MA, Repelaer van Driel OJ, Tutein Nolthenius-Puylaert MC, Vreugdenhil G, Coebergh JW.
    Ned Tijdschr Geneeskd; 1998 Aug 01; 142(31):1772-8. PubMed ID: 9856143
    [Abstract] [Full Text] [Related]

  • 16. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B, Zhang N, Naritoku WY, Tsao-Wei DD, Groshen SL, Carlsson G, Larsson L, Gustavsson B, Chaiwun B, Taylor CR, Imam SA.
    Anticancer Res; 2004 Aug 01; 24(4):2391-400. PubMed ID: 15330189
    [Abstract] [Full Text] [Related]

  • 17. Cysteine proteinase inhibitor cystatin A in breast cancer.
    Kuopio T, Kankaanranta A, Jalava P, Kronqvist P, Kotkansalo T, Weber E, Collan Y.
    Cancer Res; 1998 Feb 01; 58(3):432-6. PubMed ID: 9458085
    [Abstract] [Full Text] [Related]

  • 18. [Clinical features and prognosis in breast cancer patients over 70 years of age].
    Zhao WH, Xu BH, Li Q, Zhang P, Sun Y.
    Zhonghua Zhong Liu Za Zhi; 2006 May 01; 28(5):385-8. PubMed ID: 17045008
    [Abstract] [Full Text] [Related]

  • 19. [Correlations between estrogen receptor and prognostic factors of patients with breast cancer. The Kanto Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer, Japan].
    Tominaga T, Abe O, Izuo M, Isono K, Enomoto K, Nishi M, Fukami A, Muto T, Morioka Y, Watanabe H.
    Gan To Kagaku Ryoho; 1993 Nov 01; 20(14):2171-6. PubMed ID: 8239682
    [Abstract] [Full Text] [Related]

  • 20. Correlation of clinical, pathological status, hormone receptor and C-erbB-2 oncoprotein in breast cancer patients.
    Aryandono T, Harijadi, Ghozali A.
    Gan To Kagaku Ryoho; 2000 May 01; 27 Suppl 2():600-6. PubMed ID: 10895217
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.